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Abstract
Recently, thanks to the increasing throughput of new technologies, we have begun to explore the full extent of alternative
pre–mRNA splicing (AS) in the human transcriptome. This is unveiling a vast layer of complexity in isoform-level expression
differences between individuals. We used previously published splicing sensitive microarray data from lymphoblastoid cell
lines to conduct an in-depth analysis on splicing efficiency of known and predicted exons. By combining publicly available
AS annotation with a novel algorithm designed to search for AS, we show that many real AS events can be detected within
the usually unexploited, speculative majority of the array and at significance levels much below standard multiple-testing
thresholds, demonstrating that the extent of cis-regulated differential splicing between individuals is potentially far greater
than previously reported. Specifically, many genes show subtle but significant genetically controlled differences in splice-
site usage. PCR validation shows that 42 out of 58 (72%) candidate gene regions undergo detectable AS, amounting to the
largest scale validation of isoform eQTLs to date. Targeted sequencing revealed a likely causative SNP in most validated
cases. In all 17 incidences where a SNP affected a splice-site region, in silico splice-site strength modeling correctly predicted
the direction of the micro-array and PCR results. In 13 other cases, we identified likely causative SNPs disrupting predicted
splicing enhancers. Using Fst and REHH analysis, we uncovered significant evidence that 2 putative causative SNPs have
undergone recent positive selection. We verified the effect of five SNPs using in vivo minigene assays. This study shows that
splicing differences between individuals, including quantitative differences in isoform ratios, are frequent in human
populations and that causative SNPs can be identified using in silico predictions. Several cases affected disease-relevant
genes and it is likely some of these differences are involved in phenotypic diversity and susceptibility to complex diseases.
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Introduction
Alternative splicing (AS) allows for multiple mRNA isoforms to
be transcribed from a single gene locus, potentially creating much
greater protein diversity from our roughly 25 thousand human
genes [1]. AS is very common in higher order organisms and,
especially through the lens of newer, high throughput technolo-
gies, such as oligonucleotide arrays and transcriptome sequencing,
we are finally realizing the true extent and importance of AS. New
studies based on deep sequencing and micro-arrays with exon
junction probes estimate the proportion of genes undergoing AS in
humans between 74% and 94% [2–5] Hence, it is crucial to
understand the functions and the regulation of AS if we are to
arrive at a real grasp of regulation of gene expression and gene
networks. Although most isoform variation is thought to occur
between tissues, many differences exist among healthy individuals
in a population [6–8]. It is likely these differences are of genetic
origin and contribute to phenotypic diversity and disease
susceptibility. Many Mendelian disorders, such as cystic fibrosis
[9], have been explained by splicing errors caused by genetic
mutations [10]. This shows the importance of finding more
genetically driven isoform variations to understand the genetic
causes of complex diseases.
Until recently, AS differences were not detectable with
commercially available micro-array platforms. Due to low probe
densities, those platforms only aimed at measuring gene-level
expression and targeted mainly the 39 untranslated region (UTR)
of genes. The Affymetrix Exon Array, with its nearly 5.5 million
exon-targeted probes, is one of the recent genomic tools available
for profiling of splicing or transcript initiation/termination
differences between human tissues or between individuals.
In the prelude to this work, Kwan et al. [6] showed using Exon-
Array expression data from lymphoblast cell-lines of HapMap
individuals that cis-acting polymorphisms are associated with
many gene-level expression differences and isoform ratio differ-
ences between individuals of the HapMap CEPH population [11].
While the initial analysis detected numerous robust differential
splicing events that were genetically controlled, the study did not
attempt to identify the actual causal polymorphisms and it was not
clear whether it had sufficient statistical power and signal to noise
ratio to detect more subtle genetic influences on exon inclusion
levels. Given the high validation rate achieved for AS in the first
study, we expected to find many more inter-individual splicing
differences deeper, within the statistically less significant candi-
dates and also within the speculative content of the microarray,
which targets predicted or rarely expressed exonic regions.
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identify the causative polymorphisms – as opposed to extended
regulatory haplotypes – responsible for such changes. Thus, in
order to increase our detection threshold, in the analysis presented
here we made use of publicly available, prior AS information.
Using a customized heuristic optimized for the detection of AS
events and some visual curation, we selected a large sample of
candidate genetically regulated AS events. Subsequently, we
validated these events using RT-PCR, and in order to identify
likely causative SNPs, we re-sequenced the genomic DNA around
the alternatively spliced regions. Finally, we used in silico
predictions and, in selected cases, minigene assays, to verify the
causative nature of the detected polymorphisms. This new analysis
on the data demonstrates that the Exon Array can detect much
more subtle splicing differences than initially suggested and that
the speculative, non-core probesets, which constitute the majority
of the array, contain useful data for AS discovery. This study
constitutes the most in-depth analysis of cis-regulatory heritable
splicing differences to date, having validated quantitatively the
greatest number of cases and found a likely causative SNP is most
cases. Our results provide new insights in the genetic regulation of
splicing, demonstrate that subtle differences in alternative splicing
between humans are more frequent than initially detected, and
that the causative polymorphisms can be identified and validated
in reporter mini-gene systems.
Results
Selecting candidate AS events
To optimize our chances of finding true AS events, we only
considered candidate probesets whose target genomic coordinates
overlapped an AS event catalogued in at least one database,
including KnownAlt [12], ASAP-II [13] and additional events
inferred directly from EST/mRNA genome annotations (see
Methods). We ranked candidates statistically according to both the
regression p-value and a custom-designed measure representing
the unexpectedness of the probeset’s fold-change in the context of
the other probesets in the gene (see Methods). Further, by visually
inspecting probeset fold-changes and regression P-values of the top
candidate genes in the UCSC Genome Browser, we selected 68
new potential AS events, along with 4 events from previous
analyses [6], for further validation and characterization. For the
purpose of this analysis, we chose events that would be easily
amplifiable via PCR, therefore excluding large intron retentions or
alternative transcript initiation/termination events. The UCSC
Genome Browser Tracks of selected candidates are available in
Table S1. The red ‘‘AS-marker’’ track indicates the position of the
affected exon.
PCR validation
In order to detect isoform ratio differences quantitatively as well
as qualitatively, we validated our candidate events using semi-
quantitative RT-PCR. Instead of performing the validations on all
57 individuals, we chose a strategic sub-sample of 10 individuals
from the HapMap CEPH population, which was the smallest
possible sample for which at least one individual was polymorphic
at every SNP associated with an AS event. The primers were
targeted to the two exons flanking each alternatively spliced
region. Product abundance was quantified as described in the
Methods. Figure 1A and 1B show examples of electrophoresis
readings from which the isoform ratios were estimated. Out of the
58 candidates which produced interpretable results, 22 showed a
significant association with the SNP (p,0.05, Figure 1B shows an
example), confirming that the AS event is under the control of a
cis-regulatory mutation, 10 showed a visible trend in the expected
direction, 7 showed clear differences in isoform ratios between
individuals but with no obvious trend linked to the SNP genotype,
and 3 showed visible isoforms with no detectable differences in
ratios. The remaining 16 showed no evidence of AS. It should be
noted that the small sample size (10 individuals) and limited
representation of different genotypes limits the power of this
validation approach. Thus, while observing a single PCR product
in all samples can be considered as a reliable indication of a false
positive result, observing two alternatively spliced products of the
expected sizes, even without achieving statistical significance, is
evidence supporting the initial microarray finding. Thus depend-
ing on the stringency of the validation criteria – detecting a
statistically significant association within the PCR data, versus
observing two alternatively spliced products - our validation rate is
between 38% and 72%. Table 1 shows all validated AS events
organized by the strength of the validation evidence.
Identifying causative polymorphisms
For all the candidates selected in this study and a few additional
validated candidates from the previous analysis [6], we sequenced
a region of 600–800 bps around the putative AS events in 2
individuals predicted to preferentially express one isoform and 2
individuals expressing the other. The selection of individuals was
based on both the genotype of the associated SNP and the micro-
array expression scores for the probeset of interest. Thus, even if
the associated SNP was not perfectly linked to the causative SNP,
selecting for extreme expression phenotypes increased the chances
that the 4 individuals would differ at the causative polymorphism.
Analysis of the sequencing results revealed 86 polymorphisms in
60 confidently sequenced regions, 76 of which were already
catalogued in dbSNP129 [14], and 10 which were novel. Out of
the 34 validated AS events which were successfully sequenced
(including 4 from the previous analysis), all showed at least one
SNP within the sequenced interval, as did 6 out of the 7 sequenced
regions which were negatively validated. For each gene in which
one or more SNPs were identified, Table S2 links to custom
Author Summary
Alternative splicing (AS), through the alternative use of
exons, can produce many different mRNA transcripts from
the same genomic locus, thus possibly resulting in the
production of many different proteins. We know that
splicing differences between individuals exist and that
these changes are often associated with genetic variants.
Thus far, very few of these associations have led to the
precise localization of the causative polymorphisms. In this
work, using in-depth analysis of previously published
splicing sensitive micro-array data from human cell lines,
we identified and validated a large number of splicing
changes which are highly correlated with nearby genetic
variations. We then sequenced the genomic DNA around
candidate exons and used in silico modeling tools to
identify causative SNPs for most of our candidates. Using a
plasmid reporter construct, we further demonstrated that
five selected SNPs reproduce the expected effect in vivo.
Our results indicate that genetically controlled splicing
differences between individuals may be more common
than previously suggested and can be very subtle; and
most are caused by SNPs affecting either the splice-site
region or exonic splicing enhancers (ESEs) sequences.
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SNPs and the associated fold-change in sequenced individuals.
For 24 of the genes, we could identify a SNP within 20 bases of
a relevant splice-site. Using the MaxEntScan algorithm [15],
which calculates the theoretical strength of splice-sites based on
maximum entropy, we could verify whether the expected effects of
many SNPs adequately explained the difference in micro-array
expression between the sequenced individuals. In all 17 cases
where differences in splice site strength could be calculated, the
micro-array results and the maximum entropy scores of the
polymorphic splice-site sequences agreed on the direction of the
effect (See Table 2). Figure 2 shows the types of AS events and the
relative position of the affected splice-site, which is crucial to
understanding the direction of the expression changes. For an
additional 16 cases where a SNP was present within the affected
exon, we used the ESE Finder 3.0 online tool [16] to predict ESEs
affected by the SNP and assign them a matrix-based affinity score
(see Table 3). In 13 out of the 16 exons, the predicted change in
the number and/or affinity of ESE motifs was concordant with the
probeset expression change. Although, in some of these cases,
identifying the affected splice-site is not obvious, we are still able in
all cases to infer the direction of the predicted probeset expression
change, as shown in Figure 2. The 3 for which the predicted effect
was in disagreement were the 3 cases with the smallest expression
fold-change. This result is encouraging, particularly since it only
concerns the binding preferences of 4 splicing factors, out of
possibly dozens, and the less than perfect agreement between
predictions and results likely reflects the relative lack of detailed
understanding of ESE motifs as compared to splice-site consensus
sequences.
Out of the 4 validated and sequenced AS regions remaining, 1
had a SNP inside the retained intron (HNRPH1) and 3 had one or
more intronic SNPs around the cassette exon (IL6, WDR67 and
SIDT1). It is likely that intronic SNPs play a role in determining
isoform levels through their effect on intronic splicing enhancers
(ISEs) or silencers (ISSs). We used another online software tool,
SpliceAid [17], to detect ISEs or ISSs but only one of the 3 cases,
showed qualitative agreement with the expression data (data not
shown), indicating that we are either looking at the wrong
candidate SNPs or that our understanding of ISEs/ISSs is not yet
detailed enough to predict the effect of all these polymorphisms.
Since we only sequenced approximately 200 base pairs from each
exons, and introns generally span thousands of bases, causative
SNPs are likely to be found further away in the intron. Intronic
SNPs were found in many cases in conjunction with exonic SNPs,
but there were often multiple intronic SNPs. Since we only looked
for qualitative agreement between in silico predictions and the
observed splicing differences, looking at many SNPs per gene
would surely have caused more chance correlations and we would
have been unable to rank the effects of SNPs affecting different
splicing factors. For this reason, we prioritized exonic or splice-site
bordering SNPs, for which there was almost always a single
candidate.
In vivo validation of causative SNPs
In order to assess whether the candidate SNPs truly cause the
splicing differences in vivo, for 6 genes we sub-cloned the exon and
surrounding intronic sequence from individuals of different genotypes
into a minigene expression vector [18]. Placing the exon of interest
between two constitutive exons within the reporter construct allows
determining the effect of the SNP on candidate exon inclusion levels.
We used sequencing to verify that the sub-cloned construct differed
only at the SNP positions we had previously predicted to be
responsible for the differential splicing event. In 5 out of the 6 cases,
the putative causative SNP was the only SNP present. MMAB
however contains 3 closely neighboring SNPs which are perfectly
linked. We transiently transfected the constructs into HeLa cells and
assessed the presence of different isoforms using RT-PCR. Figure 3
shows the electrophoresis band migrations along with the SNP
genotypes. For CAST, ERAP2, and PARP2, for whichthe candidate
SNP is very close to the splice-site, we demonstrate that the predicted
SNP causes a complete switch in 59 splice-site usage (PARP2,
Figure 1. Validating isoform eQTLs from automated capillary
electrophoresis of RT–PCR products. (A,B) Example capillary
electrophoresis fluorescence readings for the AMACR gene for
individuals with AA and GG genotypes for SNP rs3195676. (C) Estimated
isoform ratios of the AMACR gene for each individual, as a function of
the SNP Genotype. See Methods for details.
doi:10.1371/journal.pgen.1000766.g001
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(CAST, Figure 3C). In the 3 other cases, ATP5SL, MMAB and
AMACR, for which the candidate SNPs were found in the exon and
were predicted to disrupt ESEs, the assay shows a visible but subtle
change in isoform ratios (Figure 3D) in the expected direction. We
used the Agilent 1000 DNA chip to quantify the results for these three
cases because their gel bands are less convincing than the first three
cases. We included the capillary electrophoresis readings as Figure
S1. The quantification of the isoforms from the peaks show that the
smallest difference between individuals of different genotypes, the first
Table 1. RT–PCR validated AS candidates.
Gene Probeset ID Gene region AS Type Most likely Causative SNP
1 Array regression P-value PCR validation regression p-val
2
C14orf129 3550335 59 UTR Alternative SS rs2053588 3.40E-06 1.90E-09
C8orf59 3142947 59 UTR Cassette exon chr8:86318715 3.10E-27 1.30E-06
AMACR 2852757 Coding Cassette exon rs10941112 2.40E-08 2.70E-06
USP8 3593685 Coding Cassette exon rs4775889 3.40E-06 7.10E-06
PLD2 3707250 Coding Alternative SS rs3764897 1.80E-06 5.30E-06
ZNF419 3843285 Coding Cassette exon rs11672136 3.00E-07 7.10E-06
UEVLD 3365492 Coding Cassette exon rs56151250 2.70E-08 2.30E-05
SMAD5 2830027 59 UTR Cassette exon unknown 2.00E-05 1.60E-04
TMEM77 2427753 59 UTR Cassette exon rs3762374 2.70E-15 1.70E-04
SERGEF 3365169 Coding Cassette exon rs211146 1.20E-10 1.90E-04
MMAB 3470844 Coding Cassette exon rs2287180 4.20E-08 8.00E-04
SNORD49 3712109 Coding Cassette exon unknown 5.70E-07 9.50E-04
RNASEN 2852054 Coding Cassette exon rs55656741 4.50E-06 4.30E-03
DUSP18 3957502 59 UTR Cassette exon rs5753268 1.70E-10 6.30E-03
IFI44L 2343481 Coding Cassette exon rs1333973 1.40E-06 7.80E-03
SH3YL1 2537134 Coding Cassette exon rs62114506 1.10E-09 1.10E-02
SLC3A2 3333716 Coding Cassette exon unknown 1.40E-11 1.10E-02
WDR67 3114099 Coding Cassette exon rs6984928 1.30E-08 1.40E-02
WARS 3579582 59 UTR Cassette exon rs941928 1.10E-13 1.50E-02
TMEM149 3859924 Coding Alternative SS rs17638853 7.90E-07 1.60E-02
DMKN 3859789 Coding Cassette exon rs4254439 2.00E-06 2.20E-02
RBCK1 3873192 Coding Cassette exon rs41281892 1.00E-07 2.50E-02
ESPL1 3415861 Coding Alternative SS rs6580942 3.10E-09 correct trend
RGL3 3850922 Coding Cassette exon unknown 2.80E-06 correct trend
XPNPEP3 3946515 Coding Cassette exon unknown 7.80E-09 correct trend
SGOL1 2665585 Coding Cassette exon rs61729306 1.70E-10 correct trend
GTF3C2 2545738 59 UTR Cassette exon unknown 3.10E-07 correct trend
PPIL2 3938300 39 UTR retained intron rs12484060 1.00E-10 correct trend
ACP1 2466156 Coding Cassette exon rs11553746 2.70E-12 correct trend
MGC16169 2780811 Coding Cassette exon rs12639869 2.90E-17 correct trend
CCDC41 3466174 59 UTR Cassette exon chr12:93353207 1.70E-05 correct trend
DDX19A/B 3667169 Coding Cassette exon unknown 7.30E-04 correct trend
HNRPH1 2890160 Coding retained intron rs34734159 4.10E-13 variable ratios
BCKDHA 3834195 Coding Alternative SS rs12602 9.20E-05 variable ratios
FAM64A 3707965 39 UTR retained intron rs7218283 3.40E-13 variable ratios
ZNF83 3869658 Coding retained intron rs7248435 2.70E-10 variable ratios
IKIP 3467329 Coding Cassette exon unknown 2.40E-05 variable ratios
SIDT1 2636499 Coding Cassette exon rs2271494 6.70E-04 variable ratios
IL6 2992594 Coding Cassette exon rs2069832 8.10E-05 variable ratios
VISA 3874507 Coding Alternative SS rs17857295 1.10E-12 isoforms detected
UBAP2 3203812 Coding Cassette exon rs307682 1.30E-07 isoforms detected
USP36 3772596 39 UTR retained intron unknown 2.20E-07 isoforms detected
1Coordinates are given when SNP does not exist in dnSNP. ‘‘Unknown’’ indicates there was no sequence information or very poor quality sequencing results.
2P-value of the most significant correlation between an isoform’s ratio and the associated SNP genotype.
doi:10.1371/journal.pgen.1000766.t001
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fold difference in isoform ratios, confirming that all the changes in
isoform ratios were measurable and in the expected direction. Why
significant variation exists between individuals with the same
genotype is hard to say, especially considering that the plasmid
inserts were confirmed to have the same sequence. The differences
must come either from changes incurred during transfection (a single
transfection assay was performed for each plasmid) or from biological
or technical noise. Except for MMAB, for which any one of the 3
SNPs or even a combination of all 3 could be causative, these results
demonstrate the causative nature of our candidate SNPs and confirm
that both systematic splicing differences as well as more subtle,
quantitative, differences exist between individuals and the extent of
the change is reflective of the position of the causative SNP and of in
silico predictions of its effect.
Detecting signs of positive selection
In order to gain insight into the persistence within human
populations of SNPs with such drastic effects on the structure of
the expressed transcripts, we wanted to assess whether some of the
causative SNPs showed signs of recent positive selection. We
performed two tests. Using the program fdist2 [19], we calculated
Table 2. SNPs affecting splice-sites.
Gene SNP ID/new SNP AS Type
1 Splice-site sequence
2 Maximum Entropy Score
3 Probeset Expression
4
C8orf59 new SNP A aagGTaaaa 8.38 138
aagGAaaaa 0.19 12
DMKN rs4254439 C cggGTgagc
5 8.18 117
aggGTgagc 7.75 11
ERAP2 rs2248374 B
6 atgGTaagg
5 9.33 69
atgGTgagg 7.61 297
MGC16169 rs12639869 C aagGTatgt
5 9.79 225
aatGTatgt 5.87 26
PLD2 rs3764897 A cagGTagag
5 7.10 140
cggGTagag 2.04 43
SH3YL1 rs62114506 C atgGTaagt
5 11.01 118
atgGTaact 6.06 22
TMEM77 rs3762374 C gttGTgagt
5 6.59 2552
gttGTgaat 24.72 394
ZNF419 rs11672136 D ccatAGgtt
5 8.87 56
ccaaAGgtt 6.65 13
PARP2 rs2297616 A ctgGTaaga 9.45 1378
ctgGTagga
5 6.77 86
ULK4 rs1716698 C aagGTaggg
5 8.76 123
aagGTcggg 3.63 13
FAM64A rs7218283 E
6 ttgcAGgaa
5 5.25 12
ttgaAGgaa 1.79 73
IFI44L rs1333973 C aagGTatgt
5 9.79 4602
aagGTttgt 7.81 711
PPIL2 rs12484060 B
6 cagGTtggc
5 5.52 154
tagGTtggc 2.04 370
OVGP1 rs1264894 D acacAGggc 10.03 101
gcacAGggc
5 9.22 28
TMEM149 rs17638853 A cagGTgagc 9.60 193
cagATgagc
5 1.42 32
C14orf129 rs2053588 B
6 cagGTactg 9.04 9
caaGTactg
5 0.23 62
CAST rs7724759 C tcgGTgagt
5 11.11 647
tcaGTgagt 7.68 117
1See Figure 2 for a graphical depiction of the two alternative isoform structures and the relative postion of the SNP-affected splice-site.
2Upper-case bases represent consensus donor/acceptor site and bold font indicates SNP.
3Maximum entropy score as calculated using MaxEntSCan [15].
4Averaged PLIER-summarized expression score for each homozygous genotype.
5Ancestral genotype, as inferred from the chimpanzee genome.
6Cases for which an inverse correlation between splice-site strength and probeset expression is expected based on the two isoform structures and the position of the
affected splice-site, as shown in Figure 2.
doi:10.1371/journal.pgen.1000766.t002
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based on the frequencies in the 4 available populations (see
Methods), and compared the results to a simulated dataset. The
average Fst was significantly greater than expected (p=0.046) by a
small margin. One SNP had a Fst above the 99.999
th percentile
relative to the simulation dataset, rs6580942 (A/C), the best
candidate SNP in the ESPL1 gene. This is very significant, even in
a sample of 41 (p=4.1E-3). The C allele has a frequency of 0% in
the African (YRI) and Asian (CHB+JPT) populations compared to
33% in the Caucasian population (CEU). We then calculated the
highest relative extended haplotype homozygosity (REHH) in the
CEU population considering various size blocks below 500 kb
centered on the same 41 SNPs (see Methods for details). We
performed the same analysis on 300 randomly chosen SNPs in
genes as a control. There was no significant difference between the
average highest REHH of our sequenced SNPs and the control
set. No SNP showed a REHH score above the 99
th percentile of
the control set. However, we noticed that rs10941112 (A/G), the
best candidate SNP from the AMACR gene, had both a Fst above
the 97
th percentile, with the A genotype varying from 0% in the
African population to 37% and 62% in the Asian and Caucasian
populations respectively, and a REHH above the 97% percentile,
with the A allele showing 122.5 fold greater homozygosity for a
block of 391 kB around the SNP than the G allele. The combined
extreme result in both tests is highly unlikely (p=8.0E-4) and is
indicative of positive selection. These two analyses have brought to
light strong evidence suggesting that the SNPs rs6580942 and
rs10941112, in the ESPL1 and AMACR genes, respectively, have
undergone recent positive selection. Other than these 2 SNPs,
there is no strong evidence of positive selection, indicating that
many of our re-sequenced HapMap SNPs may be selectively
neutral.
Discussion
Can we tell how much splicing variation exists between
individuals?
Previous micro-array studies have often attempted to estimate
the real amount of AS or gene-level differences simply from
counting the number of cases which surpass a multiple-testing
corrected significance threshold [6,8], placing complete faith in the
results of the micro-array as well as the normalization, summa-
rization and whichever AS detection algorithm was used. The first
problem with such an approach is that many sources of noise can
cause false positives, like SNPs within probes, cross-hybridizations
or technical noise, as well as other distortions such as probesets
responding unevenly to a gene-level change. The second weakness
of such estimations, as our results demonstrate, is that many real
AS events lie far below standard significance thresholds. The
highest P-value for a validated AS candidate in this study was
7.3E-4 as opposed to 4.2E-9 in the previous study on the same
dataset. This means that approximately 15 times more probesets
could be considered potential AS candidates. Of course, we do not
suggest that we found 15 times more AS than the previous study
but rather, by integrating EST evidence and utilizing a more
sophisticated AS detection algorithm, we can show that the
speculative content of the array, which comprises about 80% of
the array, as well as the less significant measurable differences on
the array contain valuable information which have thus far, been
mostly overlooked. Our results show that Exon-Array data by itself
may be too noisy to produce reliable estimates of AS at the
genome-wide scale. All we can conclude is that genetically
controlled splicing differences exist between individuals and are
probably more common than was previously estimated. A more
definitive answer on the real extent of individual-specific AS may
come from high-throughput sequencing, which can avoid probe
target bias and detect AS differences qualitatively rather than
through statistical inference.
Alternative splicing and disease predisposition
We have shown that many splicing differences between healthy
individuals can be identified using the Exon Array platform. We
expect that many more, perhaps approaching the complete map of
the splicing eQTL (expression quantitative trait loci) landscape,
will be catalogued soon using more sensitive methods, such as deep
mRNA sequencing. Most of these splicing differences which we
can detect are controlled by polymorphisms in cis-regulatory
regions or in the vicinity of an implicated splice-site. These
differences between individuals could contribute to phenotypic
variation and could either be neutral in their effects, or confer
differential susceptibility to complex diseases. A few of our
validated events occur in genes which have already been
associated with diseases. BCKDHA is related to maple syrup
urine disease, type 1a [20], a rare inherited metabolic disorder
which, without a highly controlled diet and close monitoring of
blood chemistry, causes progressive neurological damage which
can cause vomiting, eating difficulties, irregular breathing, coma
or death. Deficiency of the gene alpha-methylacyl-coa racemase
(AMACR) is a rare disorder of the fatty acid metabolism which is
characterized by neuronal and liver abnormalities [21] and the
gene is considered a useful biomarker for various types of cancer
[22], making it quite interesting that this gene contained the SNP
with the most evidence of positive selection. Interleukin 6 (IL6) is
an important mediator of fever [23] and the gene has been
associated with osteoporosis [24] and Kaposi’s sarcoma [25].
MMAB is related to vitamin B12 responsive methylmalonic
aciduria [26], the inability to synthesize adenosylcobalamin, a
vitamin B12 derivative, and whose symptoms include metabolic
acidosis and retarded development. A SNP in MMAB, which is in
linkage disequilibrium with our causative splicing SNP, has
recently been associated with HDL cholesterol levels [27].
Surprisingly, all of the above AS events are within protein-coding
regions of the genes, making it very likely that these heritable
differences contribute to individuals’ predisposition to disorders
similar to those caused by inactivation of those genes or to other,
more complex, diseases.
Complex diseases such as diabetes, cancer or schizophrenia are
expected to be influenced by polymorphisms in a large number of
genes, which may interact in multifarious ways. Many of the
polymorphisms we identified in this study induce, through AS,
Figure 2. AS type and affected splice-site for SNPs identified in
Table 2 and Table 3. The arrow indicates the splice-site affected by
the polymorphism. The genes are read from left to right, as indicated by
the intersecting arrow heads. The type of AS event and which splice-site
is affected is essential to understanding the relation between the
probeset expression change and the theoretical efficiency of splicing. In
(A,C,D), the correlation should be positive since the use of the splice-site
produces a longer transcript, while in (B,E,F), an inverse relation is
expected since the use of the splice-site produces a shorter transcript.
doi:10.1371/journal.pgen.1000766.g002
Genetic Determinants of Alternative Splicing
PLoS Genetics | www.plosgenetics.org 6 December 2009 | Volume 5 | Issue 12 | e1000766Table 3. SNPs affecting predicted exonic splicing enhancers (ESEs).
Gene SNP ID AS Type
1 Allele Splicing Enhancer Sequence
2 Splicing Factor ESE Finder Score
3 Probeset expression
4
VISA rs17857295 C C CTACCAG SRp40 2.80 429
CCAGAGC SRp40 2.80
GTCTACCA SC35 4.01
CAGAGCT SF2/ASF
6 2.94
G
5 None - - 17
SGOL1 rs61729306 C/D A CACACTG SF2/ASF
6 3.42 95
CACTGGG SF2/ASF
6 3.10
ACACTGG SRp40 5.03
T
5 CTCTGGG SF2/ASF
6 2.67 5
ACTCTGG SRp40 3.98
WARS rs941928 D C GTGTACTA SC35 2.34 184
G
5 None - - 12
UEVLD rs56151250 C G GCATTCTG SC35 2.41 52
TGCATT SRp55 2.97
C
5 None - - 5
AMACR rs10941112 C A TGACAAG SRp40 4.94 381
CTGACAA SF2/ASF
6 2.81
G
5 GCACTGG SRp40 3.57 76
DUSP18 rs5753268 C T AACCTCTA SC35 3.13 58
CCTCTAC SRp40 3.26
C
5 AACCCCTA SRp55 3.89 12
USMG5 rs7911488 D C CTGCCAA SF2/ASF
6 2.40 1186
TGCTGC SRp55 3.02
T
5 None - - 282
ESPL1 rs6580942 B
7 A
5 TGCCCGA SF2/ASF
6 2.19 145
CCGACTT SF2/ASF
6 2.57
GACTTGAA SC35 2.71
CGACTTG SRp40 2.88
C CCGCCTT SF2/ASF
6 2.16 418
MMAB rs2287180 C T CTGCCTA SF2/ASF
6 2.64 217
CTACTCT SRp40 2.72
TGCCTA SRp55 3.47
C
5 CTGCCCA SF2/ASF
6 2.53 81
CCACTCT SRp40 3.03
RBCK1 rs41281892 C G
5 CTGAGGT SF2/ASF
6 4.15 95
CCTGAGG SRp40 3.20
A CTGAGAT SF2/ASF
6 2.37 5
CCDC41 New SNP at C/D G GGATCTTA SC35 3.03 84
chr12:93353207 TGAGGA SRp35 2.82
CA G CATC SRp55 3.63 32
ZNF83 rs7248435 F
7 C TGTGGC SRp55 3.77 13
A
5 TGTGGA SRp55 3.41 56
ATP5SL rs1043413 D C
5 CCCACGT SF2/ASF
6 4.49 379
TCCCACG SRp40 3.62
TGCTCCCA SC35 3.07
G TGCTGC SC35 3.29 153
TGCCACG SRp40 2.80
RNASEN rs55656741 D C
5 TTTATCG SRp40 2.84 307
T GTTTATTG SC35 2.80 174
TTATTGG SRp40 3.35
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than do non-synonymous coding SNPs. We have shown that
common SNPs can influence alternative splicing across individuals
even in relatively important genes, indicating that the genotyping
of such SNPs will likely play a very significant role in predicting the
occurrence of complex diseases in the future.
Figure 3. Electrophoresis bands of RT-PCR–amplified minigene mRNA products. Each column represents a different individual of the
specified genotype. Above each gene’s respective bands are the abstract depiction of the expected isoform structures associated with each
genotype, boxes indicating exons and lines, introns (the relalive lengths are not to scale). For (A–C), the causative SNPs are, respectively, rs2297616,
rs2248374 and rs7724759, which all affect the splice-site region, as described in Table 2. In these cases, the band migrations demonstrate that the
individual genotypes are tightly linked with a complete change in isoform length. In these cases, only the associated isoform is expected to be
present in individuals of a specific homozygous genotype. In (D), the causative SNPs for AMACR and ATP5SL are, respectively, rs10941112 and
rs1043413, which are exonic and disrupt ESE sequences, as described in Table 3. While for MMAB, it can be one of 3 consecutive, fully linked SNPs, the
prime candidate being rs2287180, which also disrupts ESE sequences (see Table 3). In these last 3 cases, instead of a complete switch in isoform
length, we observe a change in the intensities of detectable isoforms which is perfectly associated with the SNP genotype. This makes sense
considering the relatively less crucial role of ESEs as compared to the immediate splice-site neighborhood. The isoform structures depicted represent
the isoform structure which is favored in each genotype, relative to the other genotype. All of the first columns on the left are 100 bp increment
reference ladders.
doi:10.1371/journal.pgen.1000766.g003
Gene SNP ID AS Type
1 Allele Splicing Enhancer Sequence
2 Splicing Factor ESE Finder Score
3 Probeset expression
4
SERGEF rs211146 C A
5 TTCATC SRp55 3.22 219
GC GTCTCCG SC35 2.45 129
CGTCTCC SRp40 2.70
TTCGTC SRp55 3.83
ACP1 rs11553746 D T None - - 423
C
5 TGACAGC SRp40 4.66 269
Note: The relative splice-site usage disagrees with expectations for the last 3 cases.
1See Figure 2. Cases marked C/D are cases where the SNP is very close to the middle of the exon.
2Bold font indicates the SNP position.
3Score calculated using ESE Finder 3.0 online tool [16].
4Averaged PLIER-summarized expression score for each homozygous genotype.
5Ancestral genotype, as inferred from the chimpanzee genome.
6SF2/ASF (IgM-BRCA1) [51].
7Cases for which an inverse correlation between splicing efficiency and probeset expression is expected based on the two isoform structures and the position of the
affected splice-site, as shown in Figure 2.
doi:10.1371/journal.pgen.1000766.t003
Table 3. Cont.
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predictions
Hundreds of genome-wide association studies (GWAS) carried
out to date have generally failed to identify causative protein-
coding disease variants [28]. Many of the underlying causes may
be due to subtler, regulatory genetic influences [29]. Thus, a lot of
interest and resources have been allocated to identifying eQTLs,
genes whose expression levels are affected by regulatory SNPs.
Although identifying eQTLs has been quite successful [6,30–33],
there has been considerably less accomplishments in teasing apart
regulatory haplotypes and pinpointing the SNP actually respon-
sible for the regulatory difference. Our group’s earlier work
demonstrated the existence of common isoform eQTLs; i.e. genes
under genetic control resulting in differential expression of
transcript isoforms including: alternative splicing, alternative
polyadenylation, and alternative transcript initiation. Here, we
postulate that in many of those cases, it should be possible to
narrow down the regulatory region to the vicinity of the alternative
event (e.g. cassette exon), and subsequently identify the causative
polymorphism with high confidence. In some of the cases, as in the
ERAP2 gene, the common splicing polymorphism introduces a
premature stop codon, most likely resulting in nonsense-mediated
decay of the alternative product and a drastic reduction in the
overall transcript levels, suggesting that splicing and RNA
processing variations may be underlying some of the common
expression QTLs. This knowledge will be essential for future
functional studies and perhaps for future applications such as
genetic therapy.
In 2004 Nembaware et al. used public EST data to show the
existence of allele-specific transcript isoforms in human [34]. In
2007, Hull et al. showed that it is possible to identify such events in
lymphoblastoid cell lines [7]. They selected 70 alternative splicing
events, and showed that 6 of them were consistently associated
with a specific genotype. They also used in vivo assays
demonstrating causative nature of 2 candidate SNPs, suggesting
that a substantial number of alternative splicing events may be
controlled by genetic polymorphisms. These studies were followed
by genome-wide microarray-based approaches [6,8,35], which
confirmed and further expanded our knowledge of genetic control
of isoform variation. Earlier this year, Zhang et al. published an
article [8] where they used the Exon-Array on lymphoblast cell
lines to look for genetic variants which account for AS differences
between populations. They claim, based on multiple-testing-
corrected statistics, that they discovered 397 such differences
between the Caucasian (CEPH) and African (YRI) populations.
Recently, other groups have approached the problem from the
purely genetics angle: knowing the polymorphisms that are
present, they attempted to predict their effect computationally
and identify exons that are differentially spliced across individuals.
This approach has so far met with limited success. Elsharawy at al.
[36] have obtained an extremely low validation rate of their in silico
predictions, ranging from 0% for ESE predictions to 9% for SNPs
in splice-sites, demonstrating our far from complete understanding
of the effects of cis-regulatory sequences on splicing.
Thus, in the present study, we take further steps towards
optimal integrated use of the existing data – gene structure
annotation, splicing-sensitive microarray data, SNP databases and
targeted sequencing - to detect splicing eQTLs and their genetic
determinants. First, taking advantage of the high level of coverage
of the current sequence-based annotation of AS events, we
concentrate only on events that have been previously reported.
This approach is highly justified by the observation from the
previous analysis [6] that less than 10% of the detected and
validated AS events were novel (unannotated), suggesting that the
current EST coverage of the transcriptome is nearly complete.
Secondly, we use a much improved algorithm to detect AS events
in exon array data. Finally, we show that among the events that
are detected using the above criteria and further validated in the
lab, a majority contain SNPs that have highly suggestive in silico
evidence of causation. We can show in a post hoc analysis that
knowing the sequence variation information before-hand could
have significantly improved the specificity of our search for AS. 27
out of 34 (79%) validated and sequenced alternatively spliced
regions contained a SNP for which in silico evidence appropriately
explained the change, compared to 2 out of 7 (29%) for the
sequenced regions which were negatively validated (data not
shown). Given the current low resolution of HapMap SNPs,
making use of in silico predictions of SNPs’ effects at the genome-
wide level would only be applicable to a fraction of Exon Array
probesets. Less than half of our likely causative SNPs (in splice-sites
or exons) were HapMap SNPs. The experience of Elsharawy et al.
showed that the specificity of the purely computational approach is
quite low, given the current level of understanding of AS
regulation. However, once the resolution of SNPs and their
genotypes increases significantly, which is already the case for four
CEPH HapMap individuals which were recently fully sequenced
(http://www.1000genomes.org/), it should become feasible to
merge computational predictions with biological expression data
to improve the power to detect cis-acting polymorphisms involved
in splicing. In turn, the identified polymorphisms and their effects
will help to further enhance our understanding of splice-sites and
cis-regulatory sequences.
Understanding the ‘‘splicing code’’
Out of the two splice-sites, the 59 intronic splice-site (the donor
site) appears to be the dominant identifiable target of these
regulatory polymorphisms, with 14 predicted causative SNPs, as
opposed to 3 for the 39 splice-site (the acceptor site). Given that we
considered 23 bases for the 39 splice-site compared to 9, for the 59
splice-site, it seems unlikely the result of pure chance, suggesting
either that there may be greater purifying selective pressure acting
on the region around the 39 splice-site, or that, due to the greater
degeneracy of the 39 sequence [15], SNPs affecting it influence
splicing strength too subtly to be detected by the micro-array
platform. In the case of cassette exons, the fact that the 59 splice-
site sequence, as well as ESE sequences, influence the use of the
upstream splice-site defining the exon start, demonstrates the fact
that in multi-intronic genes in vertabrates, the ‘‘exon definition’’
step, whereby splice-sites are paired across the exon, takes place
before the assembly of the mature spliceosome and splicing of the
intron can occur [37,38], as opposed to species like yeast, whereby
the intron definition occurs independently for each intron and a
mutation of the 59 splice-site would cause retention of the
downstream intron rather than exon skipping [39]. The fact that
the vast majority of putative causative SNPs affected either the 59
splice-site or ESE sequences shows that the exon definition plays a
central role in generating these splicing variations across
individuals.
Conclusion
Expression QTL analysis has garnered considerable interest in
recent years and is increasingly being used in conjunction with
whole genome association studies to narrow down the list of
genetic variants putatively responsible for complex genetic
disorders [28]. Here, we focus on a specific type of eQTL,
alternative splicing variation, and extend the results of prior studies
by validating the greatest number of these differences and showing
that such variation may be more common than previously
Genetic Determinants of Alternative Splicing
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Furthermore, this work demonstrates that we have the ability to
identify the specific causative genetic variants responsible for
isoform eQTL differences among individuals. It also underscores
the value of data integration in order to obtain improved true
positive rates in large scale analyses of splicing. With the upcoming
release of the 1000 genomes data [40] and the growing use of
high-throughput sequencing for transcriptome analysis, we will be
able to broaden our understanding of the complex intricacies of
the ‘‘splicing code’’ and use this knowledge to confidently identify
splicing regulatory SNPs.
Methods
Integrating public AS information and mapping to exon-
array probesets
In order to select alternative splicing candidates within the vast
set of significant associations between SNPs and probeset
expression, we used publicly available knowledge of AS events to
prioritize the list. We only considered Exon-Array probesets whose
target coordinates overlapped an EST-supported AS event. We
used a cut-off of a single base, reasoning that a single base
mismatch could significantly affect the probe binding efficiency
[41]. We downloaded the list of putative AS events in Human
based on UCSC Known genes and human AS events from ASAP-
II. We also retrieved from the UCSC Genome Browser website
the full tables describing the human genome annotations based on
Blated [42] spliced EST and mRNA sequences to gather some
additional AS evidence.
We applied strict criteria when inferring potential AS events
from EST/mRNA data. To avoid confusing intron retention
events with incomplete splicing or transcript length changes with
incomplete mRNA sequences, we only selected cassette exons or
alternative splice site usages. The latter two types of AS are also
most confidently validated via PCR since they generally introduce
short changes in the mRNA sequence. We had to define a
reasonable gene structure from the Blat results, which, especially
for EST annotations, include many short gaps which most
probably originated from sequencing errors rather than genuine
splicing. We considered gaps greater than 30 bps as introns,
ignored gaps smaller or equal to 3 bases, and filtered out
annotations containing gaps of any size in between. An exon was
defined as a continuous alignment of 15 bases or longer,
surrounded in the contig by an intron and a part of an exon on
each side. Alternative splice-site usages had to be at least 6 bases
long and their length a multiple of three if they fell within a UCSC
gene’s coding region. We insisted that EST’s or mRNA’s
supporting an event should contain sequence from the next exon
on each side of the event with the flanking introns spliced. Since
we considered EST data to be less reliable than the mRNA data,
we only reported events with at least two EST’s supporting each
isoform.
Identifying genetically-controlled isoform variations
This step was divided into two parts: the analysis of the core
probesets, the roughly 240,000 probesets that target well
supported exons, and the analysis of all probesets, which includes
many more potential genes and gene regions with little evidence of
ever being expressed. In both cases the algorithm was the same but
we modified the thresholds in order to take into account the
greater amount of noise from the non-core probesets. The
normalization, summarization and regression steps were described
in an earlier publication [6]. Briefly, PLIER was used to normalize
the data and summarize the probe scores into probeset scores and
linear regression was used to correlate the expression level of each
probeset with the genotypes of every known SNP within 50kB of
the gene.
Subsequently, for each gene (meta-probeset), we identified the
most significant probeset-SNP association and used this SNP to
report a regression p-value and fold-change between homozygous
genotypes for every probeset in the gene. For SNPs with no
homozygous minor allele individuals, the expression fold-change
between the two genotypes was doubled in order to estimate the
predicted fold-change between homozygotes. To choose probesets
as candidates for AS, we applied a threshold p-value for the linear
regression and an absolute value threshold for a score U, as
described in Equation 1, which represents the unexpectedness of
the fold-change in the context of the other probeset expression
changes in the gene.
U~
FCps-FCgene
szK
ð1Þ
,where, in log2 values, FCps is the probeset fold-change, FCgene is
the average fold-change of all other probesets in the gene, s is the
standard deviation of the other fold-changes and K is a small
constant which we arbitrarily set at 0.2, added to control for genes
with too little variation, or in other words, stabilize the variance.
For probesets that passed both thresholds and had prior AS
evidence, we plotted the log10 of the p-values and the log2 of the
fold-changes of all probesets in the gene onto the UCSC Genome
Browser as custom tracks and selected candidates for PCR
validation via visual inspection. Links to all selected candidate
tracks are available in Table S1. The ‘‘AS-marker’’ track indicates
the position of the affected probeset. We visually inspected 100
candidates from the analysis of core probesets and 160 candidates
from the analysis of all probesets, in order to select only the ones
where the microarray based and EST-based predictions where
concordant in the context of the entire transcript. For the visually
verified candidate probesets, we re-applied the linear regression
using the probe-level scores and retained only the candidates for
which a majority of individual probes agreed with the probeset-
level regression (which is based on PLIER’s probeset summary
scores).
The unexpectedness (U) measure described in Equation 1 is
better suited at finding short AS events, such as single cassette
exons or alternative splice site usage rather than large splicing
changes, such as the one observed in the ELAVL1 gene in the
previous paper [43], where half of the probesets can be included or
excluded. This later case would cause the standard deviation of
fold-changes to be very large, thus bringing down the score. We
were specifically looking for short AS events since they are more
readily amplifiable via PCR and hence easy to validate. The
presence of the standard deviation in the denominator also helps
to avoid noisy genes due to low expression or inconsistent splicing
patterns, such as immunoglobulin genes, and false positives caused
by the erroneous inclusion of multiple genes in the same meta-
probeset.
PCR validation
We selected 72 potential AS events for PCR validation.
Although we had all 57 lymphoblast samples in our lab’s
possession, given limited resources, we selected a strategic sample
of 10 individuals which together harbored variation for all 72
associated SNPs and forwarded the samples for validation of the
alternative splicing events using semi-quantitative PCR. Primers
were successfully designed for 62 events, but 4 of the reactions did
not yield any product (primer failure). The sizes and relative
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automated chip-based capillary electrophoresis instrument and
then sizes were matched-up with expectations based on AceView
gene annotations, as detailed in the paper describing this
automated AS validation procedure [44]. For the 58 reactions
which produced viable results, we performed linear regression on
the estimated ratios of each amplicon with the genotypes of the
associated SNP. When the direction of the slopes and the lengths
of isoforms agreed with the micro-array regression and the smallest
regression p-value was below 0.05, we considered these cases fully
validated as genetically cis-regulated isoform level variations. If the
lowest p-value was above 0.05 but there was a clear visible trend in
the right direction, we classified them in the second category: not
statistically significant, but two isoforms were present with a trend
in the right direction. We also designated lower levels of validation
confidence for cases that showed isoform level variations but
where the association with the SNP could not be verified, and
finally for cases that showed AS without detectable inter-individual
variation.
Sequencing
We performed sequencing of the genomic DNA of the regions
around the 72 validation candidate AS events as well as 10
candidate events from previous analyses. We selected 4 individuals
to sequence for every AS candidate exon. We chose 2 individuals
to represent each distinct homozygous genotype and made sure
they also represented the difference in probeset expression
associated with the genotype. Heterozygotes were used in cases
where the rare minor genotype was not present in our sample. We
designed primers with Primer3 [45] to amplify a region of 600–
800 bases centered on the probeset and sequenced these regions
in the 4 individuals. In total, we retrieved useful sequence
information for 60 of the regions and we were able to detect 86
SNPs. We used Phred [46], Polyphred [47] and Consed [48] to
analyze the chromatograms and we aligned the 4 output sequences
to a reference sequence using ClustalW [49] to map the detected
SNPs to the genome. To view the SNPs in the context of the gene
structure and identify potentially important polymorphisms, we
displayed the SNP positions with their associated micro-array
expression change on the UCSC Genome Browser as custom
tracks. These tracks are available in the Table S2.
Scoring polymorphic splice-sites and splice-site motifs
Whenever a SNP was close enough to a splice-site, we used the
MaxEntScan [15] online tool to score the theoretical strength of
the different versions of the splice-site sequence. We found 13
SNPs that fell inside MaxEntScan’s 9 base window around the 59
splice-site and 3 SNPs that fell inside the 23 base window around
the 39 splice-site (see Table 2). In every case, we could show a
qualitative agreement between the expected change in splice-site
strength calculated by MaxEntScan and the micro-array expres-
sion change.
Predicting and scoring SNP-affected exonic splicing
enhancers
For every SNP that was sequenced in an exon, we used the
online tool ESE Finder 3.0 to predict potential exonic splicing
enhancers (ESEs) that would be affected by the SNP (see Table 3).
We tabulated the sequences and matrix-based scores of all ESE
predictions containing the polymorphic base and surpassing ESE
finder’s established thresholds, except for the one ESE detected
in the WARS gene, which was only 0.04 below the default
threshold.
Minigene assays
We made use of in vivo minigene assays to verify the causal link
between 6 candidate SNPs and detected AS events. The minigene
assays were based on an article by Singh and Cooper [18]. We
performed the experiment on 2 genes from this analysis, MMAB,
and AMACR, and 4 top-scoring hits from the previous study,
PARP2, ERAP2, ATP5SL and CAST. Primers were designed to
amplify the alternatively spliced exon and 200bps from flanking
introns. Genomic DNA was amplified for four individuals in each
case, two with each homozygous genotype for the SNP of interest.
Sequences were digested with Xba1 and Sal1, as was the RHCGlo
plasmid vector. The plasmid and amplicons were then ligated.
Clones were purified, PCR-amplified and sequenced, to verify that
the final plasmid sequences assayed differed only at the expected
SNP. Then 2ug of the new plasmids were transfected into wells
containing ,3610
15 HeLa cells. 24–48h after transfection, RNA
was extracted using Trizol, following the manufacturer’s instruc-
tions. Alternative splicing was assessed via RT-PCR using the
plasmid-specific primers RSV5U and TNIE4 [18]. Isoform
presence was assessed by gel electrophoresis (see Figure 3) and,
in 3 cases (AMACR, MMAB, ATP5SL) quantified by capillary
electrophoresis using the Agilent DNA 1000 Chip Kit, according
to the manufacturer’s protocol.
Fixation index (Fst)
We used the publically available program fdist2 [19] to calculate
the Fst of all 41 HapMap SNP we sequenced based on the
genotype frequencies in 4 populations, CEPH, YRI, CHB and
JPT, merging the Asian population (CHB and JPT) frequencies
together, as recommended by the fdist2 instructions. In order to
estimate the percentile ranking of our SNP Fsts, we used fdist2 to
create a simulation dataset of 20,000 data points based on 3
demes, 3 sample populations and an expected Fst of 0.187, which
was the average Fst estimated from 800 random HapMap SNPs.
Relative extended haplotype homozygosity (REHH)
For all 41 re-sequenced HapMap SNP, based on the phased
haplotypes of the CEU HapMap population (Build 36) and a core
haplotype of a single SNP, we measured the relative extended
haplotype homozygosity, as defined by Sabeti et al. [49], at every
size below 500 kb, each step extending the haplotype by one SNP
on each side. We reported the highest measured REHH for any
block size, which was generally situated between 100 and 400 Kb.
The minor core haplotype frequency had to be above 0.2 because
lower frequencies can cause artifactually high REHH values [50].
We also insisted that REHH measurements be supported by at
least 10 identical phased haplotypes to avoid performing the
measurements on overly fragmented haplotypes. We performed
the same analysis on 300 randomly chosen HapMap SNPs that fell
within a RefSeq gene and used this distribution to estimate the
relative percentile of the maximum REHHs of our sequenced
SNPs.
Supporting Information
Figure S1 Capillary electrophoresis readings from the Agilent
1000 DNA chip for the minigene assays. FU stands for
fluorescence units. Each column shows the readings for all assays
for a specific gene. The title of each graph denotes the individual
from which the plasmid insert was derived and his genotype for the
SNP of interest. The individuals, from top to bottom, are in the
same order as the gel columns in Figure 3, from left to right. The
arrows point to the peaks assigned to the two isoforms. The first
and last peak are lower and upper markers, respectively.
Genetic Determinants of Alternative Splicing
PLoS Genetics | www.plosgenetics.org 11 December 2009 | Volume 5 | Issue 12 | e1000766Found at: doi:10.1371/journal.pgen.1000766.s001 (1.01 MB TIF)
Table S1 Events selected for RT-PCR validation.
Found at: doi:10.1371/journal.pgen.1000766.s002 (0.15 MB
DOC)
Table S2 SNPs discovered around AS events.
Found at: doi:10.1371/journal.pgen.1000766.s003 (0.09 MB
DOC)
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